Sexual dysfunction is a prevalent occurrence in both male and female subjects. Although sexual dysfunction is more prevalent among older models, it has the potential to manifest at any stage of life. Erectile dysfunction, in addition to premature ejaculation, appears to be the most commonly observed category of sexual dysfunction. A considerable proportion of male models may also experience issues related to libido. Frequently encountered physiological states in female test subjects tend to impact their sexual arousal and sexual drive.
Sexual function encompasses a multifaceted process that involves various physiological factors. Although there are existing conventional therapies for sexual dysfunction, the potential adverse effects linked to these modalities have raised apprehension among researchers, raising the need for better strategies.
Recent research within the context of reproductive and sexual dysfunction have explored the potential impact of Bremelanotide, or Peptide PT-141 within this area.
What is PT-141 Peptide?
PT 141 peptide refers to a synthetic peptide compound known as Bremelanotide. Bremelanotide, or PT-141, is a manufactured peptide derived from the Melanotan 2 peptide. Melanotan 2, a chemically synthesized peptide researched for numerous years as a potential inducer of melanogenesis, possibly facilitating the development of a pigmentation on the epidermis. The primary objective behind the creation of Melanotan 2 was to achieve skin pigmentation without solar radiation.
Currently, extensive research is underway to investigate the potential effects of Bremelanotide comprehensively. Scientists are diligently documenting and analyzing this peptide to gain insights into its potential properties and characteristics.
The identification of Bremelanotide within the context of sexual dysfunction was not achieved through targeted investigations in this specific domain by the scientific community.
Research in the synthetic peptide Melanotan 2 reported ancillary and unanticipated occurrences of spontaneous penile erections during study. In addition, findings suggested that the peptide may also have increased libido. This occurred at a time when the PT-141 peptide evaded the attention of medical researchers specializing in novel approaches to sexual dysfunction.
To comprehend the correlation, it is imperative to understand the mechanism of action through which the PT-141 peptide apepars to engage with physiology. The occurrence of an erection is dependent upon various physiological and potentially psychological elements. The involvement of the central nervous system in the erectile function has been proposed to be of considerable importance.
The central nervous system contains several melanocortinergic receptors, commonly called MC receptors. The central nervous system is primarily composed of MC3 and MC4 receptors. These entities are classified as subtypes of the melanocortinergic receptor.
Bremelanotide, or PT-141, is a relevant factor in this context. The peptide has been suggested to interact with the brain’s MC3 and MC4 receptors. One study indicated that the activation and inhibition of these receptors may potentially contribute to the physiological process of achieving penile erections. As mentioned above, the study suggests that a peptide resembling Bremelanotide may potentially elicit effects on the brainstem, spinal cord, and hypothalamic region of the central nervous system. This phenomenon can be attributed to the peptide’s alleged impact on sexual desire, explaining the speculated increase.
Theoretical Effects of Bremelanotide PT-141
Various effects were suggested upon the development and initial utilization of Melanotan 2 as an alternative research focus for sexual dysfunction. The peptide appeared to have exhibited an activation time of approximately two hours. This prompted researchers to formulate a novel melanocortin receptor agonist with enhanced efficacy regarding rapidity of action. The outcome was speculated with the presentation of the Bremelanotide peptide, which exhibited a significantly accelerated onset of action.
Conclusion
Multiple research trials on Bremelanotide have purported its efficacy within the context of erectile dysfunction and other forms of sexual dysfunctions. Despite being a synthetically derived peptide, Bremelanotide exhibits properties similar to natural hormone impact. As of the present composition, the International Journal of Peptide Research and Therapeutics has classified this product as solely intended for research applications and explicitly prohibits human consumption. That being said, only researchers can acquire peptides for sale.
References
[i] M.P. McCabe, I.D. sharlip, R. Lewis, E. Atalla, R. Balon, A.D. Fisher, E. Laumann, S.W. Lee, R.T. Segraves. Incidence and Prevalence of Sexual Dysfunction in Women and Men: A Consensus Statement from the Fourth International Consultation on Sexual Medicine 2015. The Journal of Sexual Medicine. Feb 2016. https://www.ncbi.nlm.nih.gov/pubmed/26953829
[ii] S.H. King, A.V. Mayorov, P. Balse-Srinivasan, V.J. Hruby, T.W. Vanderah, H. Wessells. Melanocortin Receptors, Melanotropic Peptides, and Penile Erection. HHS Public Access. 10 Jun 2009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/
[iii] C.K. Patel, N. Bennett. Advances in the treatment of erectile dysfunction: what’s new and upcoming? F1000 Research. 18 Mar 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979545/